title: Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype.
abstract: In Sweden, acellular pertussis vaccines were introduced at 3, 5 and 12 months of age in 1996, after a 17-year hiatus without pertussis vaccination. An intensified surveillance of pertussis was initiated in October 1997, including collection of clinical data as well as Bordetella pertussis isolates in culture or PCR-confirmed cases of pertussis among children born from January 1996 to September 2004. We analysed the association of pulsed-field gel electrophoresis (PFGE) profile and serotype with severity of disease for all children followed during the first 7 years of the project. There were in all 927 children for whom both clinical information and strain characterisation data were available. 260 of these children were hospitalised during the pertussis episode. When duration of hospital stay was compared between children with different groups of strains, characterised by PFGE profile or serotype, there was a significantly higher proportion of children with long duration of hospital stay in the most frequent PFGE profile group (BpSR11) compared to the PFGE group of all other profiles (p=0.041). There was no statistically significant association between serotype and hospitalisation rate or duration of hospital stay, neither was there any statistically significant association between serotype or PFGE profile and duration of spasmodic cough or presence of complications.
authors.affiliation: Swedish Institute for Infectious Disease Control, Tumour and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden. reza.advani@smi.ki.se
authors.forename: Abdolreza
authors.initials: A
authors.lastname: Advani
authors.forename: Lennart
authors.initials: L
authors.lastname: Gustafsson
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Carlsson
authors.forename: Declan
authors.initials: D
authors.lastname: Donnelly
authors.forename: Hans O
authors.initials: HO
authors.lastname: Hallander
mesh_terms: D001886:Bordetella pertussis / Q000737:chemistry*; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage* / Q000276:immunology; D016521:Electrophoresis, Gel, Pulsed-Field; D006801:Humans; D011159:Population Surveillance; D012703:Serotyping; D013548:Sweden / Q000453:epidemiology; D014611:Vaccination; D014917:Whooping Cough / Q000145:classification / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine